Two distinct receptor pathways, one synergistic research protocol. A mechanistic comparison of the most co-studied growth hormone secretagogue pair in the peptide literature.
Two Pathways, One Goal
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds to the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and secretion of endogenous GH. Ipamorelin binds the GHS-R1a receptor — a completely separate pathway.
Head-to-Head Comparison
Mechanism, half-life, receptor target, pulse pattern, cortisol/prolactin impact, and stacking rationale compared side by side. The combination produces synergistic GH release greater than either compound alone.
The DAC Question: Half-Life and Pulse Pattern
The DAC modification adds a lysine residue that forms a covalent bond with serum albumin, dramatically extending the half-life from ~30 minutes to approximately 6–8 days — changing the GH release pattern from pulsatile to sustained.